Latest News of EGF
Are Strong Financial Prospects The Force That Is Driving The Momentum In Siegfried Holding AG's VTX:SFZN) Stock?
By Yahoo! Finance |
1 month ago
Siegfried Holding's stock rose by 16% in the past three months. Analyzing its financial health, the Return on Equity (ROE) stands at 14%, indicating efficient profit generation and future earnings pot...
RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer
By Yahoo! Finance |
2 months ago
The FDA approved RYBREVANT in combination with chemotherapy for EGFR-mutated NSCLC patients. Results from the Phase 3 MARIPOSA-2 study showed improved outcomes, making it the third new indication for ...
Retail investors who hold 46% of Siegfried Holding AG (VTX:SFZN) gained 3.9%, institutions profited as well
By Yahoo! Finance |
2 months ago
Retail investors own 46% of Siegfried Holding AG, making them the most powerful group. Despite a recent stock price increase, institutions with 43% ownership also stand to gain. Analyzing shareholder ...
-
RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
By Yahoo! Finance | 2 months agoJohnson & Johnson announced positive results from the Phase 3 MARIPOSA-2 study, showing RYBREVANT combined with chemotherapy led to significant and sustained improvement in post-progression outcomes f...
-
Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw)
By Yahoo! Finance | 2 months agoA study by Johnson & Johnson revealed a pre-medication regimen with dexamethasone significantly reduced infusion-related reactions with RYBREVANT for NSCLC patients, showing a three-fold decrease in r...
-
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
By Yahoo! Finance | 2 months agoLong-term data from the MARIPOSA study show improved outcomes with RYBREVANT plus LAZCLUZE™ compared to osimertinib in first-line treatment for NSCLC....
-
Estimating The Fair Value Of Siegfried Holding AG (VTX:SFZN)
By Yahoo! Finance | 4 months agoAn analyst price target for Siegfried Holding AG (VTX:SFZN) is 20% above the fair value estimate. By using a Discounted Cash Flow (DCF) model, the company appears to be fairly priced based on future c...
-
Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
By Yahoo! Finance | 4 months agoThe Phase 3 PAPILLON study demonstrated that RYBREVANT with carboplatin and pemetrexed significantly enhances progression-free survival in NSCLC patients with EGFR exon 20 insertion mutations....
-
Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer
By Yahoo! Finance | 5 months agoJohnson & Johnson submitted a Biologics License Application for subcutaneous amivantamab for non-small cell lung cancer. Results from PALOMA-3 study revealed benefits like reduced infusion reactions a...